<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00482027</url>
  </required_header>
  <id_info>
    <org_study_id>A001</org_study_id>
    <nct_id>NCT00482027</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity Study of tgAAC09, a Gag-PR-RT AAV HIV Vaccine</brief_title>
  <acronym>A001</acronym>
  <official_title>A Phase 1 Randomized, Placebo-controlled, Double-blind Dose-escalation Trial to Evaluate the Safety and Immunogenicity of tgAAC09, a Gag-PR-RT AAV HIV Vaccine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>International AIDS Vaccine Initiative</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Targeted Genetics Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital of Philadelphia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nationwide Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>International AIDS Vaccine Initiative</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine safety and immunogenicity (ability to induce an&#xD;
      immune response) of a novel HIV vaccine based on adeno-associated virus (AAV)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The need for a vaccine to prevent AIDS and interrupt transmission of HIV is indisputable. To&#xD;
      be effective, an HIV vaccine will have to induce cellular and humoral immune responses that&#xD;
      are durable and potent. Intra-muscular delivery of HIV genes enclosed within recombinant&#xD;
      adeno-associated virus (rAAV) protein capsid has been shown to be a potent inducer of both&#xD;
      antibodies and T-cell responses in animal studies. tgAAC09, consisting of single-stranded DNA&#xD;
      from Clade C HIV-1 genes for the gag, protease and part of the reverse transcriptase proteins&#xD;
      enclosed within a rAAV serotype 2 protein capsid, was developed as one component of a&#xD;
      multi-component HIV vaccine. The purpose of this study is to evaluate the safety and&#xD;
      immunogenicity of tgAAC09 in healthy, HIV-seronegative volunteers.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2003</start_date>
  <completion_date type="Actual">January 2007</completion_date>
  <primary_completion_date type="Actual">December 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of one or two doses of tgAAC09</measure>
    <time_frame>One year</time_frame>
    <description>Safety of one or two doses of tgAAC09 at 3 dosage levels in a dose-escalating an ddose-optimization study</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>up to 6 months post 2nd injection</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Biodistribution</measure>
    <time_frame>upt to 6 montsh post 1st injection</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>HIV Infection</condition>
  <arm_group>
    <arm_group_label>1 AAV-2 HIV Vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>64 volunteers receiving AAV-2 HIV vaccine tgAAC09 at 3 dosage levels, dose escalation and dose optimization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>16 volunteers receiving formulation buffer consisting of a buffered salt solution with potassium phosphate, calcium chloride, magnesium chloride, and HEPES</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>tgAAC09</intervention_name>
    <description>one or 2 doses of AAV-2 HIV vaccine (tgAAC09) at 3 dosage levels, dose escalation and dose optimization</description>
    <arm_group_label>1 AAV-2 HIV Vaccine</arm_group_label>
    <other_name>AAV-2 HIV Vaccine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy males and females&#xD;
&#xD;
          -  Age at least 18 years on the day of screening and no greater than 50 years on the day&#xD;
             of vaccination&#xD;
&#xD;
          -  Available for follow-up for the planned duration of the study (screening plus 12&#xD;
             months)&#xD;
&#xD;
          -  Able to give written informed consent;&#xD;
&#xD;
          -  No reported high-risk behavior for HIV (Appendix C), willing to undergo HIV testing&#xD;
             and receive results;&#xD;
&#xD;
          -  If sexually active, willing to use or have partner use condoms from screening until at&#xD;
             least 4 months after the vaccination. Additional means of contraception are permitted&#xD;
             and encouraged.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinically relevant abnormality on history or examination including history of&#xD;
             immunodeficiency or use of immunosuppressive medication in last 6 months;&#xD;
&#xD;
          -  A chronic medical condition or concurrent condition, which, in the opinion of the&#xD;
             investigator, would make the volunteer unsuitable for the study.&#xD;
&#xD;
          -  Any of the following abnormal laboratory parameters that are mild and judged to be&#xD;
             clinically significant by the principal investigator or designee, or moderate, severe,&#xD;
             or very severe: hematology (hemoglobin, absolute neutrophil count [ANC] absolute&#xD;
             lymphocyte count [ALC], absolute CD4 count, platelets); urinalysis, clinical chemistry&#xD;
             (total bilirubin, creatinine, AST, ALT). Refer to Appendix D for the grading of these&#xD;
             laboratory parameters.&#xD;
&#xD;
          -  If female, pregnant or planning a pregnancy within 4 months after receiving the&#xD;
             vaccine, or lactating;&#xD;
&#xD;
          -  Receipt of live attenuated vaccine within 60 days or other vaccine within 14 days of&#xD;
             vaccination;&#xD;
&#xD;
          -  Receipt of other experimental HIV vaccine at any time;&#xD;
&#xD;
          -  Receipt of blood transfusion or blood products within 6 months of vaccination;&#xD;
&#xD;
          -  Participation in another clinical trial of an investigational product currently or&#xD;
             within 12 weeks of vaccination, or expected during participation in this study;&#xD;
&#xD;
          -  History of severe local or systemic reaction to vaccination or history of allergic&#xD;
             reactions to vaccines;&#xD;
&#xD;
          -  Confirmed infection with HIV-1 or HIV-2;&#xD;
&#xD;
          -  Positive for hepatitis B (surface antigen), hepatitis C antibodies, or active syphilis&#xD;
             (confirmed by treponemal test such as TPHA in addition to non-treponemal test such as&#xD;
             RPR) or active tuberculosis.&#xD;
&#xD;
          -  Unlikely to comply with protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sanjay Mehendale, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National AIDS Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nathan Clumeck, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Pierre University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jan van Lunzen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Hamburg-Eppendorf</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SGS Biopharma</name>
      <address>
        <city>Antwerpen</city>
        <zip>B-2060</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Pierre University Hospital</name>
      <address>
        <city>Brussels</city>
        <zip>B-1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univeristy of Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Hamburg</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National AIDS Research Institute</name>
      <address>
        <city>Pune</city>
        <zip>411 026</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
    <country>India</country>
  </location_countries>
  <results_reference>
    <citation>Mehendale S, van Lunzen J, Clumeck N, Rockstroh J, Vets E, Johnson PR, Anklesaria P, Barin B, Boaz M, Kochhar S, Lehrman J, Schmidt C, Peeters M, Schwarze-Zander C, Kabamba K, Glaunsinger T, Sahay S, Thakar M, Paranjape R, Gilmour J, Excler JL, Fast P, Heald AE. A phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C adeno-associated virus vaccine. AIDS Res Hum Retroviruses. 2008 Jun;24(6):873-80. doi: 10.1089/aid.2007.0292.</citation>
    <PMID>18544020</PMID>
  </results_reference>
  <verification_date>May 2007</verification_date>
  <study_first_submitted>May 31, 2007</study_first_submitted>
  <study_first_submitted_qc>June 1, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2007</study_first_posted>
  <last_update_submitted>January 14, 2013</last_update_submitted>
  <last_update_submitted_qc>January 14, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 16, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV vaccine</keyword>
  <keyword>Adeno-associated virus vactored vaccine</keyword>
  <keyword>HIV-1 subtype C</keyword>
  <keyword>Safety</keyword>
  <keyword>Immunogenicity</keyword>
  <keyword>Biodistribution</keyword>
  <keyword>HIV prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

